Submitted by Jack Attack on Fri, 08/25/2017 - 12:09pm Thank you for registering for the Live Educational Webinar titled "Aerosolized Agents for Airway Clearance in Cystic Fibrosis: When, How and Why? A Roundtable Discussion." To help our faculty provide the best possible educational experience, we have designed a survey to assess your specific learning needs. Please complete and submit this short survey before the live webinar. It will take less than 3 minutes to complete. Which of the following statements is correct? Please choose all that apply. * The primary goals of treatment in cystic fibrosis (CF) are to maintain lung function as close to normal as possible by controlling respiratory infection and inflammation and clearing airway mucus, to provide nutritional therapy to maintain adequate growth, and to manage disease complications In the era of Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulator therapy, it has been shown that there is a diminishing need for aerosolized agents for airway clearance in patients with CF Tobramycin and aztreonam are the available aerosolized agents for airway clearance in CF Agents for airway clearance improve survival by improving lung function, and preventing the occurrence of acute pulmonary exacerbations that may have negative consequences in terms of immediate morbidity Which of the following statements regarding the mechanism of action of dornase alfa, hypertonic saline and mannitol in CF is correct? * Dornase alfa corrects the defect in the CFTR gene in chromosome 7, while hypertonic saline and mannitol improve the hydration of the airway surface Dornase alfa and mannitol prevent the growth of Staphylococcus aureus and Pseudomonas aeruginosa in the airways of patients with CF, while hypertonic saline improves the hydration of the airway surface Dornase alfa and hypertonic saline improve the hydration of the airway surface, while mannitol breaks the extracellular DNA in sputum/mucus to make it less viscous Dornase alfa breaks down the extracellular DNA in sputum/mucus to make it less viscous, while hypertonic saline and mannitol improve the hydration of the airway surface Based on the AVAILABLE EVIDENCE, which of the following statements with regard to improving lung function is correct? * Dornase alfa, hypertonic saline and mannitol should always be administered after chest physiotherapy to improve lung function in patients with CF Dornase alfa, hypertonic saline and mannitol should be chronically used, alone or in combination, to improve lung function in all patients with CF irrespective of identifiable benefit There is no strong evidence to suggest that a particular timing of dornase alfa administration is clinically more effective than other timings Clinical studies have definitively indicated that hypertonic saline and mannitol are inferior than dornase alfa in improving lung function in patients with CF With regard to treatment adherence, which of the following statements is correct? Please choose all that apply. * Physicians should explore the reasons for non-adherence, and should tailor the treatment regimen to individual patients to promote adherence Patients and carers should be involved in discussing and developing their treatment plan Continued and consistent adherence to CF therapies guarantees improved patient outcomes Non-adherence to CF therapy increases the clinical, social and economic burden of the disease Electronic data capture from aerosol delivery devices is a more accurate method of measuring adherence than medication possession ratio (actual number of prescriptions retrieved compared to expected) How confident are you in your ability to educate your patients with CF on the importance of adherence to treatment? * Not at all confident Not very confident Somewhat confident Confident Very confident How confident are you in your ability to assess and monitor adherence in your patients with CF? * Not at all confident Not very confident Somewhat confident Confident Very confident Leave this field blank
